Abstract
The G protein-coupled P2Y12 receptor (P2Y12R) is an important antithrombotic target and of great interest for pharmaceutical discovery. Its recently solved, highly divergent crystallographic structures in complex either with nucleotides (full or partial agonist) or with a nonnucleotide antagonist raise the question of which structure is more useful to understand ligand recognition. Therefore, we performed extensive molecular modeling studies based on these structures and mutagenesis, to predict the binding modes of major classes of P2Y12R ligands previously reported. Various nucleotide derivatives docked readily to the agonist-bound P2Y12R, but uncharged nucleotide-like antagonist ticagrelor required a hybrid receptor resembling the agonist-bound P2Y12R except for the top portion of TM6. Supervised molecular dynamics (SuMD) of ticagrelor binding indicated interactions with the extracellular regions of P2Y12R, defining possible meta-binding sites. Ureas, sulfonylureas, sulfonamides, anthraquinones and glutamic acid piperazines docked readily to the antagonist-bound P2Y12R. Docking dinucleotides at both agonist- and antagonist-bound structures suggested interactions with two P2Y12R pockets. Thus, our structure-based approach consistently rationalized the main structure–activity relationships within each ligand class, giving useful information for designing improved ligands.
Graphical Abstract
Similar content being viewed by others
Abbreviations
- ADP:
-
Adenosine-5′-diphosphate
- ATP:
-
Adenosine-5′-triphosphate
- cAMP:
-
Cyclic adenosine monophosphate
- CHO:
-
Chinese hamster ovary
- CNS:
-
Central nervous system
- CRE:
-
cAMP response element
- ECFP:
-
Enhanced cyan fluorescent protein
- EL:
-
Extracellular loop
- GPCR:
-
G protein-coupled receptor
- MD:
-
Molecular dynamics
- POPC:
-
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
- RMSD:
-
Root-mean-square deviation
- SAR:
-
Structure–activity relationship
- SuMD:
-
Supervised molecular dynamics
- TM:
-
Transmembrane helix
- UDP:
-
Uridine-5′-diphosphate
- UTP:
-
Uridine-5′-triphosphate
References
Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA (2006) International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281–341
Burnstock G, Knight GE (2004) Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240:31–304
Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202–207
Hourani SM, Cusack NJ (1991) Pharmacological receptors on blood platelets. Pharmacol Rev 43:243–298
Jacobson KA, Deflorian F, Mishra S, Costanzi S (2011) Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal 7:305–324
Debnath B, Al-Mawsawi LQ, Neamati N (2010) Are we living in the end of the blockbuster drug era? Drug News Perspect 23:670–684
Horváth G, Gölöncsér F, Csölle C, Király K, Andó RD, Baranyi M, Koványi B, Máté Z, Hoffmann K, Algaier I, Baqi Y, Müller CE, Von Kügelgen I, Sperlágh B (2014) Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents. Neurobiol Dis pii S0969–9961(14):00175-2. doi:10.1016/j.nbd.2014.06.011
Herbert JM, Savi P (2003) P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 3:113–122
Cristalli G, Podda GM, Costanzi S, Lambertucci C, Lecchi A, Vittori S, Volpini R, Zighetti ML, Cattaneo M (2005) Effects of 5′-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors. J Med Chem 48:2763–2766
Scarborough RM, Laibelman AM, Clizbe LA, Fretto LJ, Conley PB, Reynolds EE, Sedlock DM, Jantzen H (2001) Novel tricyclic benzothiazolo[2,3-c]thiadiazine antagonists of the platelet ADP receptor (P2Y12). Bioorg Med Chem Lett 11:1805–1808
Bach P, Boström J, Brickmann K, van Giezen JJ, Hovland R, Petersson AU, Ray A, Zetterberg FA (2011) novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor. Bioorg Med Chem Lett 21:2877–2881
Bach P, Boström J, Brickmann K, van Giezen JJ, Groneberg RD, Harvey DM, O’Sullivan M, Zetterberg F (2013) Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor. Eur J Med Chem 65:360–375
Bach P, Boström J, Brickmann K, Burgess LE, Clarke D, Groneberg RD, Harvey DM, Laird ER, O’Sullivan M, Zetterberg F (2013) 5-alkyl-1,3-oxazole derivatives of 6-amino-nicotinic acids as alkyl ester bioisosteres are antagonists of the P2Y12 receptor. Future Med Chem 5:2037–2056
Bach P, Antonsson T, Bylund R, Björkman JA, Österlund K, Giordanetto F, van Giezen JJ, Andersen SM, Zachrisson H, Zetterberg F (2013) Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor, separation of the antithrombotic effect and bleeding for candidate drug AZD1283. J Med Chem 56:7015–7024
Baqi Y, Atzler K, Köse M, Glänzel M, Müller CE (2009) High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J Med Chem 52:3784–3793
Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD (2009) Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation. Bioorg Med Chem Lett 19:6148–6156
Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD (2009) Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation. Bioorg Med Chem Lett 19:4657–4663
Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Harris PK, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD (2010) Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation. J Med Chem 53:2010–2037
Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Harris PK, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD (2010) Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation. Bioorg Med Chem Lett 20:1388–1394
Zech G, Hessler G, Evers A, Weiss T, Florian P, Just M, Czech J, Czechtizky W, Görlitzer J, Ruf S, Kohlmann M, Nazaré M (2012) Identification of high-affinity P2Y12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone. J Med Chem 55:8615–8629
Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ, Willis PA, Humphries RG, Leff P, Clegg JA, Smith JA, Tomlinson W (1999) Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 42:213–220
Xu B, Stephens A, Kirschenheuter G, Greslin AF, Cheng X, Sennelo J, Cattaneo M, Zighetti ML, Chen A, Kim SA, Kim HS, Bischofberger N, Cook G, Jacobson KA (2002) Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J Med Chem 45:5694–5709
Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD, Humphries RG, Hunt SF, Ince F, Ingall AH, Kirk IP, Leeson PD, Leff P, Lewis RJ, Martin BP, McGinnity DF, Mortimore MP, Paine SW, Pairaudeau G, Patel A, Rigby AJ, Riley RJ, Teobald BJ, Tomlinson W, Webborn PJ, Willis PA (2007) From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 17:6013–6018
Ye H, Chen C, Zhang HC, Haertlein B, Parry TJ, Damiano BP, Maryanoff BE (2008) Carba-nucleosides as potent antagonists of the adenosine 5′-diphosphate (ADP) purinergic receptor (P2Y12) on human platelets. Chem Med Chem 3:732–736
Douglass JG, Patel RI, Yerxa BR, Shaver SR, Watson PS, Bednarski K, Plourde R, Redick CC, Brubaker K, Jones AC, Boyer JL (2008) Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor. J Med Chem 51:1007–1025
Douglass JG, deCamp JB, Fulcher EH, Jones W, Mahanty S, Morgan A, Smirnov D, Boyer JL, Watson PS (2008) Adenosine analogues as inhibitors of P2Y12 receptor mediated platelet aggregation. Bioorg Med Chem Lett 18:2167–2171
Kortum SW, Lachance RM, Schweitzer BA, Yalamanchili G, Rahman H, Ennis MD, Huff RM, TenBrink RE (2009) Thienopyrimidine-based P2Y12 platelet aggregation inhibitors. Bioorg Med Chem Lett 19:5919–5923
Tu W, Fan J, Zhang H, Xu G, Liu Z, Qu J, Yang F, Zhang L, Luan T, Yuan J, Gong A, Feng J, Sun P, Dong Q (2014) Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists. Bioorg Med Chem Lett 24:141–146
Zamecnik PC, Kim B, Gao MJ, Taylor G, Blackburn GM (1992) Analogues of diadenosine 5′,5′′′-P1, P4-tetraphosphate (Ap4A) as potential anti-platelet-aggregation agents. Proc Natl Acad Sci USA 89:2370–2373
Chang H, Yanachkov IB, Dix EJ, Li YF, Barnard MR, Wright GE, Michelson AD, Frelinger AL 3rd (2012) Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost 10:2573–2580
Chang H, Yanachkov IB, Dix EJ, Yanachkova M, Li Y, Barnard MR, Wright GE, Michelson AD, Frelinger AL 3rd (2014) Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5′,5′′′-P1, P4-dithio-P2, P3-chloromethylenetetraphosphate. PLoS ONE 9:e94780
Husted S, van Giezen JJ (2009) Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 27:259–274
Kauffenstein G, Hechler B, Cazenave JP, Gachet C (2004) Adenine triphosphate nucleotides are antagonists at the P2Y receptor. J Thromb Haemost 2:1980–1988
Schmidt P, Ritscher L, Dong EN, Hermsdorf T, Cöster M, Wittkopf D, Meiler J, Schöneberg T (2013) Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12. Mol Pharmacol 83:256–266
Chang H, Yanachkov IB, Michelson AD, Li Y, Barnard MR, Wright GE, Frelinger AL III (2010) Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res 125:159–165
Deflorian F, Jacobson KA (2011) Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor. J Comput Aided Mol Des 25:329–338
Zhang J, Zhang K, Gao ZG, Paoletta S, Zhang D, Han GW, Li T, Ma L, Zhang W, Müller CE, Yang H, Jiang H, Cherezov V, Katritch V, Jacobson KA, Stevens RC, Wu B, Zhao Q (2014) Agonist-bound structure of the human P2Y12 receptor. Nature 509:119–122
Zhang K, Zhang J, Gao ZG, Zhang D, Zhu L, Han GW, Moss SM, Paoletta S, Kiselev E, Lu W, Fenalti G, Zhang W, Müller CE, Yang H, Jiang H, Cherezov V, Katritch V, Jacobson KA, Stevens RC, Wu B, Zhao Q (2014) Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature 509:115–118
Chhatriwala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA, Harden TK (2004) Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther 311:1038–1043
Hoffmann K, Sixel U, Di Pasquale F, von Kügelgen I (2008) Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y12-receptor. Biochem Pharmacol 76:1201–1213
Ignatovica V, Megnis K, Lapins M, Schioth HB, Klovins J (2012) Identification and analysis of functionally important amino acids in human purinergic 12 receptor using a Saccharomyces cerevisiae expression system. FEBS J 279:180–191
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shaw DE, Shelley M, Perry JK, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749
Boldron C, Besse A, Bordes MF, Tissandié S, Yvon X, Gau B, Badorc A, Rousseaux T, Barré G, Meneyrol J, Zech G, Nazare M, Fossey V, Pflieger AM, Bonnet-Lignon S, Millet L, Briot C, Dol F, Hérault JP, Savi P, Lassalle G, Delesque N, Herbert JM, Bono F (2014) N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist. J Med Chem 57:7293–7316
Hoffmann K, Baqi Y, Morena MS, Glänzel M, Müller CE, von Kügelgen I (2009) Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. J Pharmacol Exp Ther 331:648–655
Hoffmann K, Lutz DA, Straßburger J, Baqi Y, Müller CE, von Kügelgen I (2014) Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12-receptor. J Thromb Haemost 12:1898–1905
Jacobson KA, Paoletta S, Katritch V, Wu B, Zhao Q, Stevens RC, Kiselev E (2015) Nucleotides acting at P2Y receptors: connecting structure and function. Mol Pharmacol 88:220–230
Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534–553
Sabbadin D, Moro S (2014) Supervised molecular dynamics (SuMD) as a helpful tool to depict GPCR-ligand recognition pathway in a nanosecond time scale. J Comp Inf Mod 54:372–376
Sabbadin D, Ciancetta A, Moro S (2014) Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study. J Chem Inf Model 54:2846–2855
Carugo O (2014) Buried chloride stereochemistry in the protein data bank. BMC Struct Biol 14:19
Ballesteros JA, Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors. Methods Neurosci 25:366–428
Suite Schrödinger (2014) Schrödinger. LLC, New York, NY
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(33–38):27–28
Seeber M, Felline A, Raimondi F, Muff S, Friedman R, Rao F, Caflisch A, Fanelli F (2011) Wordom: a user-friendly program for the analysis of molecular structures, trajectories, and free energy surfaces. J Comput Chem 32:1183–1194
MacKerell AD Jr, Banavali N, Foloppe N (2000) Development and current status of the CHARMM force field for nucleic acids. Biopolymers 56:257–265
Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781–1802
Post JM, Alexander S, Wang YX, Vincelette J, Vergona R, Kent L, Bryant J, Sullivan ME, Dole WP, Morser J, Subramanyam B (2008) Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res 122:533–540
Acknowledgments
This research was supported by the National Institutes of Health (Intramural Research Program of the NIDDK and R01HL077707).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Paoletta, S., Sabbadin, D., von Kügelgen, I. et al. Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information. J Comput Aided Mol Des 29, 737–756 (2015). https://doi.org/10.1007/s10822-015-9858-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-015-9858-z